Guggenheim analyst Subbu Nambi raised the firm’s price target on GeneDx (WGS) to $115 from $88 and keeps a Buy rating on the shares. The price target increase reflects the tailwind and upside associated with the American Academy of Pediatrics guideline update, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.